Matthew Kowgier - AstraZeneca (Canada)

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 5 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Durvalumab Plus Carboplatin/paclitaxel Followed by Durvalumab with or Without Olaparib As a Firstline Treatment for Endometrial Cancer: Overall Survival and Additional Secondary Efficacy En‑dpoints by Mismatch Repair Status in the DUO-E/GOG-3041/ENGOT-EN10 Trial

Jean-Francois Baurain,Hye Sook Chon,Jessica Thomes Pepin,Michael Sundborg,Michael Gold,Byoung-Gie Kim,Stephanie Blank,Ji-Hong Liu,Michael McCollum,Masahiko Mori, Goda Jonuskiene, Kathleen Moore,Zoltan Novak, Pedro Luis Ramos Guette, Charles Andreé Joseph de Pádua,Marta Gil Martin,Matthew Kowgier,Paula Michelle del Rosario,Shannon Westin,Els Van Nieuwenhuysen

Gynecologic Oncology (2024)

Cited0Views0Bibtex

Durvalumab + Carboplatin/paclitaxel (CP) Followed by Durvalumab ± Olaparib As First-Line Treatment for Newly Diagnosed Advanced or Recurrent Endometrial Cancer (EC) in DUO-E: Results by BRCA1/BRCA2 Mutation (brcam) Status

Els Van Nieuwenhuysen,Jean-Francois Baurain,Hye Sook Chon,Jessica Thomes Pepin,Michael J. Sundborg,Michael A. Gold,Byoung-Gie Kim,Stephanie V. Blank,Ji-Hong Liu,Michael McCollum,Masahiko Mori, Goda Jonuskiene,Kathleen N. Moore,Zoltan Novak, Pedro Ramos, Charles Andree, Joseph de Padua,Marta Gil-Martin,Matthew Kowgier,Paula Michelle del Rosario,Shannon Neville Westin

Journal of Clinical Oncologyno. 16_suppl (2024): 5595-5595

Cited0Views0Bibtex

Safety and Tolerability of Durvalumab + Carboplatin/paclitaxel Followed by Durvalumab ± Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (EC) in the DUO-E/GOG-3041/ENGOT-EN10 Trial

Jessica Thomes Pepin, Hye Sook Chon,Michael J. Sundborg,Michael A. Gold,Byoung-Gie Kim,Stephanie V. Blank,Ji-Hong Liu,Michael McCollum,Masahiko Mori,Kathleen N. Moore, Julian Rivera Diaz, Charles Andree Joseph de Padua,Jeronimo Martinez-Garcia,Christos Papadimitriou, Karin Grian,Robert Poka,Matthew Kowgier,Emma Oscroft,Els Van Nieuwenhuysen,Shannon Neville Westin

Journal of Clinical Oncologyno. 16_suppl (2024): 5599-5599

Cited0Views0Bibtex

LB001/#1593 Durvalumab Plus Carboplatin/paclitaxel Followed by Durvalumab With/without Olaparib for Endometrial Cancer: Mismatch Repair Deficient And/or Microsatellite Instability-High Subpopulation Efficacy Analyses from the DUO-E Trial

Els Van Nieuwenhuysen, Kathleen Moore,Todd Tillmanns, Christen Haygood,Setsuko Chambers, Anna Priebe, Young Kim,Brian Slomovitz, Goda Jonuškienė,Maria Pilar Barretina-Ginesta, Csőszi Tibor,Flora Zagouri, Jae-Weon Kim,Qinglei Gao,Fernando Contreras Mejia, Andreia Cristina De Melo,Tadaaki Nishikawa,Matthew Kowgier, Vivian Ying Wang,Shannon Westin

Late-Breaking Abstracts (2024)

Cited0Views0Bibtex

LB002/#1594 Durvalumab Plus Carboplatin/paclitaxel Followed by Durvalumab With/without Olaparib in Endometrial Cancer: Exploratory Analyses of Biomarker/histological Heterogeneity and Efficacy in the DUO-E Mismatch Repair Proficient Subpopulation

Shannon Westin, Kathleen Moore, Hye Sook Chon,Jessica Thomes Pepin, Erin Salinas,David Starks,Paul Disilvestro,Brian Slomovitz, Elen Vettus, Fernando Gálvez Montosa, Kofi Agyemang-Prempeh,Flora Zagouri, Jae-Weon Kim,Qinglei Gao,Fernando Contreras Mejia, Andreia Cristina De Melo,Tadaaki Nishikawa,Matthew Kowgier, Sonia Iyer, Els Van Nieuwenhuysen

Late-Breaking Abstracts (2024)

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn